Report
Description
Report Description
Recently, a drug called belimumab has been approved by FDA after 50 years long gap specifically
for SLE on March 9, 2011. It is the first ever targeted biological drug for the treatment of SLE
patients developed by Human Genome Sciences Inc. in collaboration with GlaxoSmithKline. It
will be the primary driver for global systemic lupus erythematous drugs market growth in the
US, France, Germany, Italy Spain, the UK and Japan. Benlysta will lead market sales in coming
years because of its excellent safety profile as well as proven efficacy in clinical trials. NSAIDS
such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE.
Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral
(Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE
treatment. Additionally, the entry of four first-in-class (FIC) biologics such as Bristol-Myers
Squibb’s Orencia (abatacept), atacicept, epratuzumab and LY2127399 are anticipated to show a
major role in the expansion of the global systemic lupus erythematous drugs market.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1149
Systemic Lupus Erythematous (SLE) Drugs Market: Key Players
The global systemic lupus erythematous drugs market key players are Anthera
Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics,
Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.